Michael Schmidt, an analyst from Guggenheim, maintained the Buy rating on Zentalis Pharmaceuticals. The associated price target is $6.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Schmidt has given his Buy rating due to a combination of factors, primarily the advancing clinical profile of azenosertib in ovarian cancer and the increasing clarity on the DENALI Part 2 program. The upcoming dose selection in 1H26 and the plan to enroll approximately 70 patients at the chosen dose create a defined path toward topline data that management believes could support an accelerated approval by year-end 2026.
The initiation of the MUIR Phase 1b combination trial in ovarian cancer and the planned ASPENOVA Phase 3 confirmatory study, both progressing on schedule, further strengthen the long-term value proposition. Together, these catalysts, along with a structured development strategy across Phase 1b, Part 2 of DENALI, and the Phase 3 program, underpin Schmidt’s favorable risk‑reward view on Zentalis Pharmaceuticals and justify his Buy recommendation.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZNTL in relation to earlier this year.